U.S. Pregnancy Urine Rapid Diagnostic Test Market - By Product Type, By Concentration, By Distribution Channel, By End Use - Forecast, 2025 - 2034

U.S. Pregnancy Urine Rapid Diagnostic Test Market Size

The U.S. pregnancy urine rapid diagnostic test market was estimated at USD 371.1 million in 2024. The market is expected to grow from USD 388.8 million in 2025 to USD 623.5 million in 2034, at a CAGR of 5.4% during the forecast period, owing to the increasing literacy rates among women, technological advancement in the development of more accurate rapid urine pregnancy diagnostic kits, and rising demand for at-home testing solutions.
 

The growth of the market is highly attributed due to the rising rate of literacy among the women across the country. Education plays a significant role among women population in order to utilize and perceive pregnancy rapid diagnostic tests. The high rate of literacy among women helps them to understand the accuracy, functionality, and reliability of these type of rapid pregnancy diagnostic kits, fostering the adoption as well as acceptance of at-home pregnancy testing as a first step in confirming the pregnancy.
 

For instance, as per the 2022 data published in the National Center for Education Statistics (NCES), the enrollment rate for higher education by female surpassed the male enrollment, with female encompassing around 59% of all U.S. college students. Therefore, as the rate of women enrollment in education increases so does the acceptance and adoption of these test among the educated reproductive age group women is anticipated to increase and propel the market in the forward direction. Moreover, the ability of the literate women to read the instructions pertaining to the test and interpret the results correctly and make an informed decisions further accelerating the adoption of over-the-counter urine pregnancy tests.
 

Moreover, technological advancement in rapid diagnostics, which is estimated to reach USD 50 billion by 2032, further stimulates the market growth of the country in the forward direction. Technological innovations such as AI-powered analytics, biosensors, digital pregnancy tests, and smartphone integrated diagnostics enhancing accuracy, reducing error, and expanding the accessibility across both retail and healthcare settings. Pregnancy urine rapid diagnostic test are medical instruments that help determine the pregnancy by checking for human chorionic gonadotropin (hCG) hormone in urine sample. These kits are effective and provide results within minutes especially without the need for personnel.
 

U.S. Pregnancy Urine Rapid Diagnostic Test Market Trends

• The rising demand of at home pregnancy urine rapid diagnostic tests in the country is stimulated by various factors such as privacy, convenience, and technological advancements. Most of women residing in the U.S. opting for at home pregnancy testing, where they can undertake the process of testing privately and comfortably.   
   
• For instance, as per the 2020 data from Statista, approximately 7.92 million women across the U.S. used home pregnancy test. This trend is anticipated to continue as the homecare rapid urine diagnostic test provide accessible and user-friendly option for women of reproductive age group.
   
• Moreover, the growing awareness pertaining to the early pregnancy detection in the U.S. is one of the key catalysts that is accelerating the growth and adoption of these test among women in the country. Early detection of the pregnancy helps women to make informed decision about their health and reproductive care, ensuring the better outcome for both the baby and mother.
   
• Additionally, various awareness campaigns have been a key catalyst for the early detection of the pregnancy among women in the country.
   
• For instance, as per the guidelines released by the American College of Obstetricians and Gynecologists (ACOG), emphasizes the early detection of pregnancy will help women to undertake and engage in vital health intervention such as folic acid intake, proper nutrition, and avoiding harmful substance, which significantly improve the pregnancy outcome.
   
• Therefore, as the awareness of the early pregnancy detection increases so does the demand for advanced rapid urine pregnancy diagnosis kits, fostering the market growth in the country.
   

U.S. Pregnancy Urine Rapid Diagnostic Test Market Analysis

In 2021, the market was valued at USD 326.6 million. The following year, it saw a slight increase to USD 339.7 million, and by 2023, the market further climbed to USD 354.5 million. Based on product type, the market is segmented into strip, cassette, and midstream test stick. The midstream test segment dominated the market with the largest revenue share of 55% in 2024 and is expected to grow at a CAGR of 5.6% over the forecast period.
 

• The growth of the segment is highly attributed due to the accuracy, convenience and ease of use offered by the midstream test. These test sticks are designed for direct urine sampling, offering a user friendly and mess-free solution for pregnancy detection.
   
• Moreover, one of the major advantages of these sticks is their straightforward application. Women using this stick need to place the absorbent end of the stick into the urine stream, making it easier to use as compared to traditional test strips-based pregnancy testing. Additionally, this test surpasses the need for separate collection containers, making the process more hygienic and convenient, especially in home settings.
   
• Midstream test sticks, such as Clearblue’s early digital pregnancy test, offer over 99% accuracy and provide reliable results. This test stick features smartcard technology which includes extra wide tip for easy sampling and floodguard technology to prevent over sampling. This stick is designed to detect the concentration of hCG hormone at level as low as 10mlU/ml.
   
• Thus, such technological advancement of the midstream test sticks contributing to the rapid adoption among women of reproductive age group, propelling the segmental growth in the forward direction.

Based on concentration, the U.S. pregnancy urine rapid diagnostic test market is bifurcated into 10 mlU/ml, 20 mlU/ml, and 25 mlU/ml. The 10 mlU/ml segment held a revenue of USD 44.8 million in 2024 and is expected to reach USD 76.1 million by 2034.
 

• Pregnancy rapid urine diagnostic tests with 10 mlU/mL sensitivity can detect hCG at a very lower level compared to other tests with higher thresholds. This sensitivity allows women to detect the pregnancy as soon as 6-8 days post ovulation, providing an advantage for women seeking for early confirmation of the pregnancy.
   
• Moreover, 10 mlU/mL sensitivity is significantly crucial in various clinical settings, especially in the IVF treatment, wherein early detection of pregnancy aids in timely treatments.
   
• Additionally, these types of tests with high sensitivity play a significant role in detecting and monitoring high-risk pregnancies and enabling timely medical intervention.
   
• Therefore, the rising demand for accurate and early pregnancy detection kits in the country is significantly increasing the adoption of 10 mlU/mL pregnancy urine rapid diagnostic test kits, since these kits provide early, rapid and accurate confirmation of pregnancy at very less concentration of hCG in the urine.
   

Based on distribution channel, the U.S. pregnancy urine rapid diagnostic test market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies dominated the market with the largest revenue of USD 184.6 million in 2024 and is expected to grow at a CAGR of 5.2% over the forecast period.
 

• The growth of the segment is highly attributed due to the widespread accessibility and convenience offered by the retail pharmacies in the U.S.
   
• Majority of the consumers of rapid diagnostic kits prefer purchasing the over-the-counter pregnancy kits form retail pharmacies due to various advantages offered such as privacy and quick access of the kits.
   
• Additionally, many retail pharmacies provide a wide variety of branded and affordable options, which is often coupled with promotional pricing and customer loyalty programs, further propelling the purchase of the pregnancy diagnostic kits from retail pharmacies.
   
• Moreover, the rising number of retail pharmacies in the U.S. is also positively contributing to the growth of the market in the country. For instance, as per the 2021 estimates there were 60,000 retail pharmacies in the U.S.
   
• Thus, as the number of retail pharmacies increases in the U.S. so does the accessibility of the rapid pregnancy diagnostic kits among the reproductive women population, accelerating the segmental growth in the forward direction.
   

Based on end use, the U.S. pregnancy urine rapid diagnostic test market is bifurcated into hospitals, specialty clinics, homecare, and other end users. The homecare segment dominated the market with the largest revenue of USD 245.1 million in 2024 and is expected to grow at a CAGR of 5.6% over the forecast period.
 

• The growth of the segment is owing to the rising preference for early pregnancy detection, the rapid pregnancy diagnostic tests pertaining to home care settings address a variety of needs, allowing women to detect early pregnancies with convenience and ease. These tests offer patients greater independence, enabling proactive decision-making and early intervention without the need for clinical visits.
   
• Additionally, the pandemic accelerated the adoption of home-based pregnancy testing, since women adopted for safer and more convenient alternatives then in clinic visits.
   
• Moreover, technological innovation in test accuracy and user-friendly formats such as digital displays and early detection capabilities have enhanced consumer confidence in home testing, further fostering the segments growth.
   

U.S. Pregnancy Urine Rapid Diagnostic Test Market Share

The top 6 companies in the market such as Church & Dwight, SPD Swiss Precision Diagnostics, Cardinal Health, SEKISUI CHEMICAL, QuidelOrtho, Abbott Laboratories account for a 60% market share. These companies have strong brand reputation along with technical expertise; thus, they have established consumer trust. Moreover, emerging participants are implementing various growth strategies such as collaborations, partnerships, and acquisitions and mergers, to strengthen offerings as well as gain a competitive edge over others. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

U.S. Pregnancy Urine Rapid Diagnostic Test Market Companies

Some of the eminent market participants operating in the U.S. pregnancy urine rapid diagnostic test industry include:

• Abbott Laboratories
• Cardinal Health
• Church & Dwight
• Danaher Corporation
• McKesson Corporation
• Medline Industries
• Meridian Bioscience
• QuidelOrtho
• Rapigen
• SEKISUI CHEMICAL
• SPD Swiss Precision Diagnostics
• Thermo Fisher Scientific

• Abbott Laboratories is a company with a strong global presence. The company operates in 160 and more countries, leading to widespread availability of products such as pregnancy test kits.
   
• Thermo Fisher Scientific is known for its expertise in diagnostics. The company offers highly accurate pregnancy detection kits, leveraging its strong research and development capabilities to enhance sensitivity and reliability in results.
   

U.S. Pregnancy Urine Rapid Diagnostic Test Industry News:

• In October 2024, Church & Dwight’s First Response launched the Multi Check Pregnancy Test Kit, featuring EasyCup, an innovative sample collection cup with a built-in test strip for enhanced convenience. The kit included two Rapid Result pregnancy tests for quick and reliable results. This innovation strengthened First Response’s market position by enhancing user convenience and boosting consumer trust.
   

The U.S. pregnancy urine rapid diagnostic test market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Strip
• Cassette
• Midstream test stick

Market, By Concentration

• 10 mlU/ml
• 20 mlU/ml
• 25 mlU/ml

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Market, By End Use

• Hospitals
• Specialty clinics
• Homecare
• Other end use